Physician profile
Ryan E Manson
NPI 1164701876
$343.37
in general payments reported to CMS, 2019-2025
10 companies · $24.54 in 2025
The $24.54 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $62.14 · 2023: $42.87 · 2024: $43.19 · 2025: $24.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $115.25 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.12 | 2021-2022 | |
| Abiomed | $43.19 | 2024 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.24 | 2021 | |
| Ardelyx, INC. | $24.54 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $15.85 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.10 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $14.98 | 2023 | Bylvay |
| Merck Sharp & Dohme LLC | $13.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.79 | 2023 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Manson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.